Background Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib)
in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement …

5508 Background: MTC arises from parafollicular cells of the thyroid gland, accounts for 5-
8% of thyroid cancers and represents an unmet medical need. Cabozantinib (cabo) is an …

Purpose Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor
(MET), vascular endothelial growth factor receptor 2, and rearranged during transfection …

BACKGROUND Cabozantinib significantly prolonged progression‐free survival (PFS)
versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P< …

Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth
factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti …

Background: Management of patients with advanced medullary thyroid cancer (MTC)
remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) vandetanib and …

Background: A limited number of approved therapeutic options are available to metastatic
medullary thyroid cancer (MTC) patients, and the response to conventional chemotherapy …

Medullary thyroid cancer arises from calcitonin-producing C-cells and accounts for 3–5% of
all thyroid cancers. The discovery of a locally advanced medullary thyroid cancer that is not …

Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular
endothelial growth factor receptor (VEGFR) and approved for radioiodine (RAI)-refractory …

Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …